Abstract: A method of producing a tablet which comprises sterols and stanols includes the steps of forming the sterols and/or stanols, separately or together, into spherically-shaped, substantially uniform beads or prills and directly compressing the beads or prills into a tablet core.

Abstract: Sterol and stanol nitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed nitro derivatives are synthesized by ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound.

Abstract: Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl moiety to make the compound more readily soluble in aqueous and non-aqueous media.

Abstract: A composition comprises one or more free (unesterified) phytosterols and/or phytostanols which are substantially completely dissolved in one or more esterified phytosterols and/or phytostanols. The present invention further provides a composition comprising one or more esterified phytosterols and/or phytostanols which are substantially completely dissolved in an edible oil.

Abstract: A composition for use in softgel capsules comprises one or more esters of phytosterols and/or phytostanols which have been treated to enhance their flowability at ambient temperatures prior to or concurrent with softgel formation.

Abstract: A stable emulsion in which an aqueous phase has one or more phytosterols or phytostanols, or mixtures thereof in free (non-esterified) form and an oil or fat phase has phytosterols or phytostanols, or mixtures thereof, in esterified form.

Abstract: A composition for use in foods, beverages and nutraceuticals that includes one or more non-sterol emulsifiers, each having an HLB value of greater than 14 and one or more sterols or stanols or mixtures thereof.

Abstract: The present invention provides, in one aspect, novel derivatives comprising sterols and/or stanols and an NSAID selected from salicylic acids and arylalkanoic acids, including salts of these derivatives, and having one or more of the following formulae: 1

Abstract: The present invention provides novel derivatives comprising compounds in the androstane and androstene series, coupled with ascorbic acid, including salts thereof, and represented by one or more of the general formulae: 1

Abstract: A process for isolating and purifying phytosterols and phytostanols from tall oil pitch is disclosed which comprises the following steps:

Abstract: Novel phytosterol and/or phytostanol derivatives, including salts thereof, are represented by the general formulae: 1

Abstract: The present invention provides a esterified and subsequently hydrogenated phytosterol composition for use alone or for incorporation into foods, beverages, pharmaceuticals, nutraceuticals, and the like. The composition has the advantage of enhanced solubility/dispersability, increased molar potency and enhanced stability over naturally isolated phytosterol compositions. Methods for the esterification and subsequent hydrogenation of the phytosterols are also provided.

Abstract: A novel process for the fermentation of phytosterol compositions to androstenedione (androst-4-ene-3,17-dione, AD) and/or androstadienedione (androsta-1,4-diene-3,17-dione, ADD) is disclosed. The process utilizes the micro-organism Mycobacterium MB 3683, and selected suitable solubilizing agents such as polypropylene glycol or silicone for solubilizing the phytosterol compositions at high concentrations in the nutrient medium. The innoculum of Mycobacterium MB 3683 is grown in a nutrient medium comprising Refiners molasses and inorganic salts.

Abstract: A method of preventing and/or delaying the onset of Alzheimer's disease in an animal comprises administering to the animal a phytosterol composition. A composition useful for preventing and/or delaying the onset of Alzheimer's disease in an animal comprises a phytosterol composition.

Abstract: Methods are provided for determining whether a subject animal has an increased risk of cardiovascular or related disorder. The level of serum campesterol and beta-sitosterol are determined and a campesterol/beta-sitosterol ratio obtained. The ratio determined for the subject animal is compared with that of a normal control animal and correlated with the risk of cardiovascular or a related disorder.